J_2000 schreef op 21 maart 2017 12:28:
Zonet in de Benelux Morning Note van KBC Bolero..
News:
MDxH announced that they have signed a non-exclusive distribution agreement to make SelectMDx (Prostate Cancer) available to Lab21 Clinical Laboratory’s urology clients in the UK. The samples will be tested in MDxHealth’s clinical diagnostic laboratory in Nijmegen (The Netherlands). Lab21 will reimburse MDxHealth for all testing services provided.
MDxHealth estimates that around 40,000 men each year undergo an unnecessary prostate biopsy and risk its associated complications.
Our View/Conclusion:
Additional expansion of the distribution agreements for SelectMDx and its reimbursement is always welcomed. It seems that the engine of SelectMDx is running smoothly at this point with only two weeks ago also news regarding the uptake of the SelectMDx test in a ground-breaking US prostate risk clinic (Michigin Medicine). We look forward to see additional deals and of them materialisation in the quarterly numbers. No change in investment case and target price of € 6.5 per share and Buy rating reiterated.